Companies: 10,795·Total market cap: $144.5T
NovoCure Limited

NovoCure Limited

NVCRNASDAQHealthcare● Active
$17.53
+$0.37(+2.16%)
Market Cap$2.0B
P/E Ratio—
52W High$19.25
52W Low$9.82
SEC Filings

NovoCure Limited (NVCR) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001645113 · NVCR · NASDAQ · as of Jun 8, 2026

Filing snapshot

1,000+
Total Filings
8-K
Latest Form
2026-06-05
Most Recent
2015
Filing Since
FinancialsEarningsView All on EDGAR

Source: SEC EDGAR (data.sec.gov) · CIK 0001645113 · Updated hourly · Not investment advice

Latest Annual Report

10-K · Annual ReportFY
Filed Date
2026-02-26
Fiscal Year End
Feb 26, 2026
Accession No.
0001645113-26-000017
Primary Document
nvcr-20251231.htm
View on SEC EDGARDownload PDFFiling Index
Source: data.sec.gov · CIK 0001645113 · Accession 0001645113-26-000017

Latest Key Filings

10-QQuarterly Report
10-Q
2026-04-30
View 10-Q on SEC
8-KCurrent Report
8-K
2026-06-05Material Event
View 8-K on SEC
Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

View Insider Trades Tab

SEC Filing History

Hide Form 4 / 144
8-KCurrent Report
8-K
2026-06-05
View
DEFA14AProxy Statement (Additional)
DEFA14A
2026-05-21
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-05-08
View
8-KCurrent Report
8-K
2026-04-30
View
10-QQuarterly Report
10-Q
2026-04-30
View
SCHEDULE 13GSCHEDULE 13G
SCHEDULE 13G
2026-04-28
View
8-K/ACurrent Report (Amended)
8-K
2026-04-24
View
DEFA14AProxy Statement (Additional)
DEFA14A
2026-04-20
View
DEF 14AProxy Statement
DEF 14A
2026-04-20
View
8-KCurrent Report
8-K
2026-04-09
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-03-26
View
8-KCurrent Report
8-K
2026-03-26
View
S-8Employee Stock Plan Registration
S-8
2026-02-26
View
10-KAnnual Report
10-K
2026-02-26
View
8-KCurrent Report
8-K
2026-02-26
View
Showing 1–15 of 302 filingsForm 4 / 144 hidden· 1000 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001645113  |  Exchange: NASDAQ · Healthcare

NovoCure Limited (NASDAQ: NVCR) has submitted 1,000+ documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2015. As a Healthcare sector company with CIK 0001645113, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is NovoCure Limited's most comprehensive regulatory disclosure. The most recent NovoCure Limited 10-K was filed on 2026-02-26 for fiscal year ending 2026. Historical NVCR 10-K annual reports are available from 2017 through 2026.

Investors researching NovoCure Limited SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-08
Related Companies SEC Filings — Healthcare
ESTA SEC Filings →NEOG SEC Filings →PLSE SEC Filings →STAA SEC Filings →BLFS SEC Filings →TDOC SEC Filings →KMTS SEC Filings →AZTA SEC Filings →
→ NVCR Financials→ NVCR Earnings→ NVCR Insider Trades

Frequently Asked Questions

NVCR SEC Filings · 8 questions

NovoCure Limited (NVCR) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 1,000+ filings and access original documents at no cost. NovoCure Limited's CIK is 0001645113.

NVCR SEC filingsNovoCure Limited SEC documentsfind NVCR 10-K